Usual Adult Dose for Human Papillomavirus Prophylaxis

Cervarix(R):
Females, up to 25 years old: 0.5 mL, intramuscularly, at 0, 1, and 6 months

Gardasil(R):
Females and males, up to 26 years: 0.5 mL, intramuscularly, at 0, 2, and 6 months

Gardasil 9(R):
Females and males, up to 45 years: 0.5 mL, intramuscularly, at 0, 2, and 6 months

Uses: For the prevention of cervical, vulvar, and anal cancer caused by Human Papillomavirus (HPV) in females, and prevention of anal cancer, genital warts, and anal intraepithelial neoplasia cause by HPV in males.

Usual Pediatric Dose for Human Papillomavirus Prophylaxis

Cervarix(R):
Females, aged 9 to 25 years: 0.5 mL, intramuscularly, at 0, 1, and 6 months

Gardasil(R):
Females and males, aged 9 to 26 years: 0.5 mL, intramuscularly, at 0, 2, and 6 months

Gardasil 9(R):
Females and males, aged 9 to 14 years: 0.5 mL, intramuscularly, at 0, and 6 to 12 months (2 dose regimen)
OR
Females and males, aged 9 to 14 years: 0.5 mL, intramuscularly, at 0, 2, and 6 months (3 dose regimen)

Females and males, aged 15 to 45 years: 0.5 mL, intramuscularly, at 0, 2, and 6 months

Comments:

• For patients aged 9 to 14: If the second Gardasil 9(R) dose is given earlier than 5 months after the first dose, administer a third dose at least 4 months after the second.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 9 years.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure like activity, has been reported following vaccination with human papillomavirus vaccine. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Minimum interval between the first and second dose of vaccine is 4 weeks; minimum interval between the second and third dose of vaccine is 12 weeks, minimum interval between first and third dose of the vaccine is 24 weeks.

If the vaccine series is interrupted and only one dose was given, administer the second dose as soon as possible and give the third dose at least 12 weeks later. If the vaccine series is interrupted and the first two doses were given, administer the third dose as soon as possible. Inadequate doses or doses received following a shorter than recommended dosing interval should be repeated. The HPV vaccine series should be completed with the same product whenever possible.